Shiva Hemmati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shiva Hemmati has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Abdolali Mohagheghzadeh
Department of Phytopharmaceuticals, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz 71345-1583, Iran
12 shared publications Issa Sadeghian
Biotechnology Incubator, Shiraz University of Medical Sciences, Shiraz, Iran
7 shared publications- Thomas Jürgen Schmidt
University of Münster, Institute of Pharmaceutical Biology and Phytochemistry, PharmaCampus, Corrensstrasse 48, D-48149 Münster, Germany
7 shared publications Yasaman Behzadipour
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
7 shared publicationsA. Wilhelm Alfermann
Institut für Entwicklungs- und Molekularbiologie der Pflanzen, Heinrich-Heine-Universität Düsseldorf, Universitätsstrasse 1, D-40225 Düsseldorf, Germany
6 shared publications- Younes Ghasemi
Department of Pharmaceutical Biotechnology, Shiraz University of Medical Sciences, Shiraz, Iran
6 shared publications
Latest Publications
- 1 September 2026
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 198 (11) , 9293-9311
Non-Covalent Active Mixing as a Viable Alternative to Covalent Conjugation for the Intracellular Delivery of Biologics: The Case of Glucarpidase
- 1 September 2026
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 198 (11) , 9293-9311
Non-Covalent Active Mixing as a Viable Alternative to Covalent Conjugation for the Intracellular Delivery of Biologics: The Case of Glucarpidase
- Open Access
The NeuroImmunoEndocrine Circuit of Umami Peptides: A Systems Biology Approach
Background/Objectives: Umami peptides enhance flavor and contribute to appetite regulation (satiety) and metabolic health. By signaling to the orbitofrontal cortex, umami has been shown to improve cognitive function in Alzheimer’s disease dementia. This taste boosts the immune system and induces saliva secretion. However, the molecular mechanisms linking umami peptides to systemic physiology remain poorly understood. This study provides the first integrated analysis of neurological, immunological, and endocrinological pathways activated by umami peptides. Methods: Novel umami peptides were identified using machine-learning and deep-learning analyses from a library of marine-derived bioactive peptides. T1R1-T1R3 heterodimer is the dominant receptor for umami taste transmission in humans, expressed on taste cells, intestinal cells, and hypothalamic tanycytes. Molecular docking confirmed the binding of novel ligands to the T1R1-T1R3 receptor complex. New candidates and experimentally validated umami peptides, identified by sensomics approaches from tauco, chicken soup, pufferfish, and dry-cured ham, were analyzed using gene ontology. Results: The functional enrichment analysis revealed crosstalk among key signaling processes, including glutamatergic and opioidergic pathways. In addition to the role of µ1 opioid receptor (OPRM1), hub gene intersections highlight cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1), and the anorexigenic pro-opiomelanocortin (POMC) neurons as potential regulators of the gut–brain axis in satiety signaling. Chemokine-encoding genes, melanin-concentrating hormone (MCH), oxytocin (OXT), and neurotensin (NTS) were other key target genes. Conclusions: The identified targets reveal the coordinated crosstalk between peripheral and central umami signaling that may contribute to the regulation of feeding behavior, satiety, cognition, memory, learning, and immune function. These network-based insights generate hypotheses and guide the design of nutritional and drug-like effectors for metabolic and cognitive health.
Open AccessThe NeuroImmunoEndocrine Circuit of Umami Peptides: A Systems Biology Approach
Background/Objectives: Umami peptides enhance flavor and contribute to appetite regulation (satiety) and metabolic health. By signaling to the orbitofrontal cortex, umami has been shown to improve cognitive function in Alzheimer’s disease dementia. This taste boosts the immune system and induces saliva secretion. However, the molecular mechanisms linking umami peptides to systemic physiology remain poorly understood. This study provides the first integrated analysis of neurological, immunological, and endocrinological pathways activated by umami peptides. Methods: Novel umami peptides were identified using machine-learning and deep-learning analyses from a library of marine-derived bioactive peptides. T1R1-T1R3 heterodimer is the dominant receptor for umami taste transmission in humans, expressed on taste cells, intestinal cells, and hypothalamic tanycytes. Molecular docking confirmed the binding of novel ligands to the T1R1-T1R3 receptor complex. New candidates and experimentally validated umami peptides, identified by sensomics approaches from tauco, chicken soup, pufferfish, and dry-cured ham, were analyzed using gene ontology. Results: The functional enrichment analysis revealed crosstalk among key signaling processes, including glutamatergic and opioidergic pathways. In addition to the role of µ1 opioid receptor (OPRM1), hub gene intersections highlight cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1), and the anorexigenic pro-opiomelanocortin (POMC) neurons as potential regulators of the gut–brain axis in satiety signaling. Chemokine-encoding genes, melanin-concentrating hormone (MCH), oxytocin (OXT), and neurotensin (NTS) were other key target genes. Conclusions: The identified targets reveal the coordinated crosstalk between peripheral and central umami signaling that may contribute to the regulation of feeding behavior, satiety, cognition, memory, learning, and immune function. These network-based insights generate hypotheses and guide the design of nutritional and drug-like effectors for metabolic and cognitive health.
- Open Access
- 1 August 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 190, 118394
Cytokines, chemokines, and immune cells involved in oral immunity towards the dental cariogenic bacterium Streptococcus mutans: Therapeutic interventions and vaccination
- 1 August 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 190, 118394
Open AccessCytokines, chemokines, and immune cells involved in oral immunity towards the dental cariogenic bacterium Streptococcus mutans: Therapeutic interventions and vaccination
- 4 June 2025
- Published by Springer Nature in Molecular Biotechnology
- Vol. 68 (3) , 1424-1444
Toward the Development of a Biosimilar Variant of Glucarpidase (Carboxypeptidase G2): Secretory Production, Optimization, and Immobilization
Carboxypeptidase G2 (CPG2) detoxifies high-dose methotrexate in cancer or autoimmune therapies. Additionally, CPG2 activates prodrugs at the tumor site in engineered CAR-T cell therapy. Since CPG2 cleaves glutamate from the substrate, it also has potential applications in enhancing food flavors and developing biosensors. However, cytoplasmic expression of recombinant CPG2 often leads to inclusion body formation, necessitating secretory production to improve product quality and streamline downstream industrial processes. This study aimed to perform a comprehensive in silico analysis to identify an optimal signal peptide for CPG2 secretion. The pelB leader sequence was selected for excretory production using the pET22b vector in Escherichia coli. The enzyme was successfully secreted into both the periplasmic space of bacterial cells and the culture medium with activities of about 0.038 UmL‒1 and 0.0285 UmL‒1, respectively. Optimal expression conditions were achieved at 25 °C with 0.5-mM IPTG, leading to enhanced yields. In the second step, we aimed to optimize the culture media composition. Therefore, a statistical design of experiments (DOE) approach in Modde software was conducted, evaluating eleven variables via a fractional factorial design (FFD). A central composite face (CCF) design was applied to establish an empirical model for maximizing periplasmic CPG2 production. The final aim was to immobilize the whole E. coli cells in calcium alginate beads for higher metabolic activity, improved growth rates, and plasmid stability. Engineered bacterial cells were entrapped in a mixture of sodium alginate and calcium chloride solution and incubated at 4 °C, 400 rpm for 60 min. Immobilization of CPG2-producing E. coli cells in 2% (w/v) calcium alginate beads yielded spherical beads, maintaining enzyme stability for 10 days, with peak activity on day 5. Conclusively, improved CPG2 solubility, facilitated protein purification, and enzyme stability over multiple reaction cycles offer a cost-effective solution for industrial purposes.
- 4 June 2025
- Published by Springer Nature in Molecular Biotechnology
- Vol. 68 (3) , 1424-1444
Toward the Development of a Biosimilar Variant of Glucarpidase (Carboxypeptidase G2): Secretory Production, Optimization, and Immobilization
Carboxypeptidase G2 (CPG2) detoxifies high-dose methotrexate in cancer or autoimmune therapies. Additionally, CPG2 activates prodrugs at the tumor site in engineered CAR-T cell therapy. Since CPG2 cleaves glutamate from the substrate, it also has potential applications in enhancing food flavors and developing biosensors. However, cytoplasmic expression of recombinant CPG2 often leads to inclusion body formation, necessitating secretory production to improve product quality and streamline downstream industrial processes. This study aimed to perform a comprehensive in silico analysis to identify an optimal signal peptide for CPG2 secretion. The pelB leader sequence was selected for excretory production using the pET22b vector in Escherichia coli. The enzyme was successfully secreted into both the periplasmic space of bacterial cells and the culture medium with activities of about 0.038 UmL‒1 and 0.0285 UmL‒1, respectively. Optimal expression conditions were achieved at 25 °C with 0.5-mM IPTG, leading to enhanced yields. In the second step, we aimed to optimize the culture media composition. Therefore, a statistical design of experiments (DOE) approach in Modde software was conducted, evaluating eleven variables via a fractional factorial design (FFD). A central composite face (CCF) design was applied to establish an empirical model for maximizing periplasmic CPG2 production. The final aim was to immobilize the whole E. coli cells in calcium alginate beads for higher metabolic activity, improved growth rates, and plasmid stability. Engineered bacterial cells were entrapped in a mixture of sodium alginate and calcium chloride solution and incubated at 4 °C, 400 rpm for 60 min. Immobilization of CPG2-producing E. coli cells in 2% (w/v) calcium alginate beads yielded spherical beads, maintaining enzyme stability for 10 days, with peak activity on day 5. Conclusively, improved CPG2 solubility, facilitated protein purification, and enzyme stability over multiple reaction cycles offer a cost-effective solution for industrial purposes.
- 28 February 2025
- Published by Elsevier in Biotechnology Advances
- Vol. 81, 108545
Expanding the cryoprotectant toolbox in biomedicine by multifunctional antifreeze peptides
- 28 February 2025
- Published by Elsevier in Biotechnology Advances
- Vol. 81, 108545
Expanding the cryoprotectant toolbox in biomedicine by multifunctional antifreeze peptides
- 3 September 2024
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 16 (6) , 2269-2304
The Roadmap of Plant Antimicrobial Peptides Under Environmental Stress: From Farm to Bedside
Antimicrobial peptides (AMPs) are the most favorable alternatives in overcoming multidrug resistance, alone or synergistically with conventional antibiotics. Plant-derived AMPs, as cysteine-rich peptides, widely compensate the pharmacokinetic drawbacks of peptide therapeutics. Compared to the putative genes encrypted in the genome, AMPs that are produced under stress are active forms with the ability to combat resistant microbial species. Within this study, plant-derived AMPs, namely, defensins, nodule-specific cysteine-rich peptides, snakins, lipid transfer proteins, hevein-like proteins, α-hairpinins, and aracins, expressed under biotic and abiotic stresses, are classified. We could observe that while α-hairpinins and snakins display a helix-turn-helix structure, conserved motif patterns such as β1αβ2β3 and β1β2β3 exist in plant defensins and hevein-like proteins, respectively. According to the co-expression data, several plant AMPs are expressed together to trigger synergistic effects with membrane disruption mechanisms such as toroidal pore, barrel-stave, and carpet models. The application of AMPs as an eco-friendly strategy in maintaining agricultural productivity through the development of transgenes and bio-pesticides is discussed. These AMPs can be consumed in packaging material, wound-dressing products, coating catheters, implants, and allergology. AMPs with cell-penetrating properties are verified for the clearance of intracellular pathogens. Finally, the dominant pharmacological activities of bioactive peptides derived from the gastrointestinal digestion of plant AMPs, namely, inhibitors of renin and angiotensin-converting enzymes, dipeptidyl peptidase IV and α-glucosidase inhibitors, antioxidants, anti-inflammatory, immunomodulating, and hypolipidemic peptides, are analyzed. Conclusively, as phytopathogens and human pathogens can be affected by plant-derived AMPs, they provide a bright perspective in agriculture, breeding, food, cosmetics, and pharmaceutical industries, translated as farm to bedside.
- 3 September 2024
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 16 (6) , 2269-2304
The Roadmap of Plant Antimicrobial Peptides Under Environmental Stress: From Farm to Bedside
Antimicrobial peptides (AMPs) are the most favorable alternatives in overcoming multidrug resistance, alone or synergistically with conventional antibiotics. Plant-derived AMPs, as cysteine-rich peptides, widely compensate the pharmacokinetic drawbacks of peptide therapeutics. Compared to the putative genes encrypted in the genome, AMPs that are produced under stress are active forms with the ability to combat resistant microbial species. Within this study, plant-derived AMPs, namely, defensins, nodule-specific cysteine-rich peptides, snakins, lipid transfer proteins, hevein-like proteins, α-hairpinins, and aracins, expressed under biotic and abiotic stresses, are classified. We could observe that while α-hairpinins and snakins display a helix-turn-helix structure, conserved motif patterns such as β1αβ2β3 and β1β2β3 exist in plant defensins and hevein-like proteins, respectively. According to the co-expression data, several plant AMPs are expressed together to trigger synergistic effects with membrane disruption mechanisms such as toroidal pore, barrel-stave, and carpet models. The application of AMPs as an eco-friendly strategy in maintaining agricultural productivity through the development of transgenes and bio-pesticides is discussed. These AMPs can be consumed in packaging material, wound-dressing products, coating catheters, implants, and allergology. AMPs with cell-penetrating properties are verified for the clearance of intracellular pathogens. Finally, the dominant pharmacological activities of bioactive peptides derived from the gastrointestinal digestion of plant AMPs, namely, inhibitors of renin and angiotensin-converting enzymes, dipeptidyl peptidase IV and α-glucosidase inhibitors, antioxidants, anti-inflammatory, immunomodulating, and hypolipidemic peptides, are analyzed. Conclusively, as phytopathogens and human pathogens can be affected by plant-derived AMPs, they provide a bright perspective in agriculture, breeding, food, cosmetics, and pharmaceutical industries, translated as farm to bedside.
- Open Access
- 8 June 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 176, 116910
Covalent conjugation and non-covalent complexation strategies for intracellular delivery of proteins using cell-penetrating peptides
- 8 June 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 176, 116910
Open AccessCovalent conjugation and non-covalent complexation strategies for intracellular delivery of proteins using cell-penetrating peptides
- Open Access
- 2 February 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (2) , 201
Immunomodulatory Peptides as Vaccine Adjuvants and Antimicrobial Agents
The underdevelopment of adjuvant discovery and diversity, compared to core vaccine technology, is evident. On the other hand, antibiotic resistance is on the list of the top ten threats to global health. Immunomodulatory peptides that target a pathogen and modulate the immune system simultaneously are promising for the development of preventive and therapeutic molecules. Since investigating innate immunity in insects has led to prominent achievements in human immunology, such as toll-like receptor (TLR) discovery, we used the capacity of the immunomodulatory peptides of arthropods with concomitant antimicrobial or antitumor activity. An SVM-based machine learning classifier identified short immunomodulatory sequences encrypted in 643 antimicrobial peptides from 55 foe-to-friend arthropods. The critical features involved in efficacy and safety were calculated. Finally, 76 safe immunomodulators were identified. Then, molecular docking and simulation studies defined the target of the most optimal peptide ligands among all human cell-surface TLRs. SPalf2-453 from a crab is a cell-penetrating immunoadjuvant with antiviral properties. The peptide interacts with the TLR1/2 heterodimer. SBsib-711 from a blackfly is a TLR4/MD2 ligand used as a cancer vaccine immunoadjuvant. In addition, SBsib-711 binds CD47 and PD-L1 on tumor cells, which is applicable in cancer immunotherapy as a checkpoint inhibitor. MRh4-679 from a shrimp is a broad-spectrum or universal immunoadjuvant with a putative Th1/Th2-balanced response. We also implemented a pathway enrichment analysis to define fingerprints or immunological signatures for further in vitro and in vivo immunogenicity and reactogenicity measurements. Conclusively, combinatorial machine learning, molecular docking, and simulation studies, as well as systems biology, open a new opportunity for the discovery and development of multifunctional prophylactic and therapeutic lead peptides.
- 2 February 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (2) , 201
Open AccessImmunomodulatory Peptides as Vaccine Adjuvants and Antimicrobial Agents
The underdevelopment of adjuvant discovery and diversity, compared to core vaccine technology, is evident. On the other hand, antibiotic resistance is on the list of the top ten threats to global health. Immunomodulatory peptides that target a pathogen and modulate the immune system simultaneously are promising for the development of preventive and therapeutic molecules. Since investigating innate immunity in insects has led to prominent achievements in human immunology, such as toll-like receptor (TLR) discovery, we used the capacity of the immunomodulatory peptides of arthropods with concomitant antimicrobial or antitumor activity. An SVM-based machine learning classifier identified short immunomodulatory sequences encrypted in 643 antimicrobial peptides from 55 foe-to-friend arthropods. The critical features involved in efficacy and safety were calculated. Finally, 76 safe immunomodulators were identified. Then, molecular docking and simulation studies defined the target of the most optimal peptide ligands among all human cell-surface TLRs. SPalf2-453 from a crab is a cell-penetrating immunoadjuvant with antiviral properties. The peptide interacts with the TLR1/2 heterodimer. SBsib-711 from a blackfly is a TLR4/MD2 ligand used as a cancer vaccine immunoadjuvant. In addition, SBsib-711 binds CD47 and PD-L1 on tumor cells, which is applicable in cancer immunotherapy as a checkpoint inhibitor. MRh4-679 from a shrimp is a broad-spectrum or universal immunoadjuvant with a putative Th1/Th2-balanced response. We also implemented a pathway enrichment analysis to define fingerprints or immunological signatures for further in vitro and in vivo immunogenicity and reactogenicity measurements. Conclusively, combinatorial machine learning, molecular docking, and simulation studies, as well as systems biology, open a new opportunity for the discovery and development of multifunctional prophylactic and therapeutic lead peptides.
- Open Access
- 11 August 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 166, 115292
Glucarpidase (carboxypeptidase G2): Biotechnological production, clinical application as a methotrexate antidote, and placement in targeted cancer therapy
- 11 August 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 166, 115292
Open AccessGlucarpidase (carboxypeptidase G2): Biotechnological production, clinical application as a methotrexate antidote, and placement in targeted cancer therapy
- Open Access
- 15 June 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (6) , 887
Hypericum perforatum L. and the Underlying Molecular Mechanisms for Its Choleretic, Cholagogue, and Regenerative Properties
Any defects in bile formation, secretion, or flow may give rise to cholestasis, liver fibrosis, cirrhosis, and hepatocellular carcinoma. As the pathogenesis of hepatic disorders is multifactorial, targeting parallel pathways potentially increases the outcome of therapy. Hypericum perforatum has been famed for its anti-depressive effects. However, according to traditional Persian medicine, it helps with jaundice and acts as a choleretic medication. Here, we will discuss the underlying molecular mechanisms of Hypericum for its use in hepatobiliary disorders. Differentially expressed genes retrieved from microarray data analysis upon treatment with safe doses of Hypericum extract and intersection with the genes involved in cholestasis are identified. Target genes are located mainly at the endomembrane system with integrin-binding ability. Activation of α5β1 integrins, as osmo-sensors in the liver, activates a non-receptor tyrosine kinase, c-SRC, which leads to the insertion of bile acid transporters into the canalicular membrane to trigger choleresis. Hypericum upregulates CDK6 that controls cell proliferation, compensating for the bile acid damage to hepatocytes. It induces ICAM1 to stimulate liver regeneration and regulates nischarin, a hepatoprotective receptor. The extract targets the expression of conserved oligomeric Golgi (COG) and facilitates the movement of bile acids toward the canalicular membrane via Golgi-derived vesicles. In addition, Hypericum induces SCP2, an intracellular cholesterol transporter, to maintain cholesterol homeostasis. We have also provided a comprehensive view of the target genes affected by Hypericum’s main metabolites, such as hypericin, hyperforin, quercitrin, isoquercitrin, quercetin, kaempferol, rutin, and p-coumaric acid to enlighten a new scope in the management of chronic liver disorders. Altogether, standard trials using Hypericum as a neo-adjuvant or second-line therapy in ursodeoxycholic-acid-non-responder patients define the future trajectories of cholestasis treatment with this product.
- 15 June 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (6) , 887
Open AccessHypericum perforatum L. and the Underlying Molecular Mechanisms for Its Choleretic, Cholagogue, and Regenerative Properties
Any defects in bile formation, secretion, or flow may give rise to cholestasis, liver fibrosis, cirrhosis, and hepatocellular carcinoma. As the pathogenesis of hepatic disorders is multifactorial, targeting parallel pathways potentially increases the outcome of therapy. Hypericum perforatum has been famed for its anti-depressive effects. However, according to traditional Persian medicine, it helps with jaundice and acts as a choleretic medication. Here, we will discuss the underlying molecular mechanisms of Hypericum for its use in hepatobiliary disorders. Differentially expressed genes retrieved from microarray data analysis upon treatment with safe doses of Hypericum extract and intersection with the genes involved in cholestasis are identified. Target genes are located mainly at the endomembrane system with integrin-binding ability. Activation of α5β1 integrins, as osmo-sensors in the liver, activates a non-receptor tyrosine kinase, c-SRC, which leads to the insertion of bile acid transporters into the canalicular membrane to trigger choleresis. Hypericum upregulates CDK6 that controls cell proliferation, compensating for the bile acid damage to hepatocytes. It induces ICAM1 to stimulate liver regeneration and regulates nischarin, a hepatoprotective receptor. The extract targets the expression of conserved oligomeric Golgi (COG) and facilitates the movement of bile acids toward the canalicular membrane via Golgi-derived vesicles. In addition, Hypericum induces SCP2, an intracellular cholesterol transporter, to maintain cholesterol homeostasis. We have also provided a comprehensive view of the target genes affected by Hypericum’s main metabolites, such as hypericin, hyperforin, quercitrin, isoquercitrin, quercetin, kaempferol, rutin, and p-coumaric acid to enlighten a new scope in the management of chronic liver disorders. Altogether, standard trials using Hypericum as a neo-adjuvant or second-line therapy in ursodeoxycholic-acid-non-responder patients define the future trajectories of cholestasis treatment with this product.